The Parallel Structure–Activity Relationship Screening of Three Compounds Identifies the Common Agonist Pharmacophore of Pyrrolidine Bis-Cyclic Guanidine Melanocortin-3 Receptor (MC3R) Small-Molecule Ligands
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241210145 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Mark D Ericson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry & Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA. Hauptthemen laut MEDLINE: Receptor, Melanocortin, Type 3, Pharmacophore. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH.
Abstract (Originalsprache)
The melanocortin receptors are involved in numerous physiological pathways, including appetite, skin and hair pigmentation, and steroidogenesis. In particular, the melanocortin-3 receptor (MC3R) is involved in fat storage, food intake, and energy homeostasis. Small-molecule ligands developed for the MC3R may serve as therapeutic lead compounds for treating disease states of energy disequilibrium. Herein, three previously reported pyrrolidine bis-cyclic guanidine compounds with five sites for molecular diversity (R1–R5) were subjected to parallel structure–activity relationship studies to identify the common pharmacophore of this scaffold series required for full agonism at the MC3R. The R2, R3, and R5 positions were required for full MC3R efficacy, while truncation of either the R1 or R4 positions in all three compounds resulted in full MC3R agonists. Two additional fragments, featuring molecular weights below 300 Da, were also identified that possessed full agonist efficacy and micromolar potencies at the mMC5R. These SAR experiments may be useful in generating new small-molecule ligands and chemical probes for the melanocortin receptors to help elucidate their roles in vivo and as therapeutic lead compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry & Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
- Center for Translational Science, Florida International University, Port St. Lucie, FL 34987, USA.
- Department of Mathematics, Nova Southeastern University, Fort Lauderdale, FL 33314, USA.
ORCID-Profile: Mark D Ericson, Carrie Haskell-Luevano
Förderung
- NIDDK NIH HHS
- NIH
Zitieren
APA
Ericson, M. D., Freeman, K. T., LaVoi, T. M., Donow, H. M., Santos, R. G., Giulianotti, M. A., Pinilla, C., Houghten, R. A., & Haskell-Luevano, C. (2023). The Parallel Structure–Activity Relationship Screening of Three Compounds Identifies the Common Agonist Pharmacophore of Pyrrolidine Bis-Cyclic Guanidine Melanocortin-3 Receptor (MC3R) Small-Molecule Ligands. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241210145
Vancouver
Ericson MD, Freeman KT, LaVoi TM, Donow HM, Santos RG, Giulianotti MA, et al. The Parallel Structure–Activity Relationship Screening of Three Compounds Identifies the Common Agonist Pharmacophore of Pyrrolidine Bis-Cyclic Guanidine Melanocortin-3 Receptor (MC3R) Small-Molecule Ligands. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241210145
BibTeX
@article{Ericson2023,
author = {Ericson, Mark D and Freeman, Katie T and LaVoi, Travis M and Donow, Haley M and Santos, Radleigh G and Giulianotti, Marc A and Pinilla, Clemencia and Houghten, Richard A and Haskell-Luevano, Carrie},
title = {The Parallel Structure–Activity Relationship Screening of Three Compounds Identifies the Common Agonist Pharmacophore of Pyrrolidine Bis-Cyclic Guanidine Melanocortin-3 Receptor (MC3R) Small-Molecule Ligands},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241210145}
}
EUVIMED